Ray Dalio
INDV icon

Ray Dalio’s Indivior Pharmaceuticals INDV Stock Holding History

Ray Dalio’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
+37,141
New +$1.23M 0.01% 771

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ray Dalio's INDV Position: Q1 2026 in Review

Ray Dalio opened a new position in Indivior Pharmaceuticals (INDV) in Q1 2026: 37,141 shares worth $1.13M. The stake represents 0.01% of the portfolio and ranks #771 among its holdings.

289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Ray Dalio held 37,141 shares of Indivior Pharmaceuticals worth $1.13M as of Q1 2026.
  • Indivior Pharmaceuticals was a new Ray Dalio position in Q1 2026.
  • Indivior Pharmaceuticals made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #771 holding.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.